iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti

iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy

Published:2020-11-04 Issue:568 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Cichocki Frank¹^ORCID,Bjordahl Ryan²,Gaidarova Svetlana²,Mahmood Sajid²,Abujarour Ramzey²,Wang Hongbo¹^ORCID,Tuininga Katie¹,Felices Martin¹,Davis Zachary B.¹,Bendzick Laura¹,Clarke Raedun²^ORCID,Stokely Laurel²^ORCID,Rogers Paul²,Ge Moyar²,Robinson Megan²^ORCID,Rezner Betsy²,Robbins David L.²^ORCID,Lee Tom T.²^ORCID,Kaufman Dan S.³^ORCID,Blazar Bruce R.⁴^ORCID,Valamehr Bahram²^ORCID,Miller Jeffrey S.¹^ORCID

Affiliation:

1. Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.

2. Fate Therapeutics, San Diego, CA 92121, USA.

3. Department of Medicine, Division of Regenerative Medicine, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

4. Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.

Abstract

Natural killer cells derived from iPSCs prime T cells for anti–PD-1 immune checkpoint therapy.

Funder

National Heart, Lung, and Blood Institute

National Cancer Institute

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference62 articles.

1. Overcoming T cell exhaustion in infection and cancer